Unusual paraneoplastic syndromes in pancreatic cancer: a case report of Lambert-Eaton myasthenic syndrome (LEMS) associated with intraductal papillary mucinous cancer of the pancreas.

Lambert-Eaton syndrome Pancreatic cancer case report paraneoplastic syndromes (PNS)

Journal

AME case reports
ISSN: 2523-1995
Titre abrégé: AME Case Rep
Pays: China
ID NLM: 101730832

Informations de publication

Date de publication:
2023
Historique:
received: 10 12 2022
accepted: 09 06 2023
medline: 9 11 2023
pubmed: 9 11 2023
entrez: 9 11 2023
Statut: epublish

Résumé

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of the neuromuscular junction. It can occur as a paraneoplastic disorder associated with various types of carcinomas, usually small cell lung cancer or as an autoimmune disease. LEMS can be misdiagnosed as myasthenia gravis or as an oncological sequela, causing delays in diagnosis. We present a rare case of a male adult with confirmed LEMS occurring with pancreatic carcinoma. A 66-year-old man presented with a newly diagnosed pancreatic tumor. He had been experiencing weakness and fatigue in his lower extremities since the summer of 2020. Over time, the weakness progressed to include his proximal upper extremity muscles. Dysphonia, dysarthria, decreased appetite and significant weight loss were also observed. A computed tomography (CT) scan revealed a 3 cm locally resectable cystic tumor in the pancreatic head. Blood tests showed elevated carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) levels. A Whipple procedure was performed, which revealed a poorly differentiated pancreatic adenocarcinoma inside an intraductal pancreatic mucinous neoplasm. Postoperatively, the patient was admitted to the intensive care unit (ICU) because he had no spontaneous breathing and manifested areflexia signs. A train of four (TOF) monitoring of peripheral nerve stimulation was performed and pyridostigmine therapy was initiated, leading to an improvement in symptoms allowing the extubation and transfer to the peripheral ward. Further diagnostic tests revealed a LEMS and an intravenous therapy with cumulative 100 g immunoglobulin (Ig) G was initiated. Upon discharge, 10 days after starting LEMS treatment, the patient showed subjective and objective improvement in strength. Paraneoplastic syndromes are more common than expected, but rare in pancreatic adenocarcinoma. They can appear before abdominal symptoms, facilitating early diagnosis. Successful treatment of cancer may eliminate paraneoplastic symptoms. LEMS may reveal pancreatic cancer. Early recognition of paraneoplastic syndromes is important for pancreatic cancer management. Further investigation is needed to evaluate the diagnostic approach for LEMS in all patients with pancreatic cancer.

Sections du résumé

Background UNASSIGNED
Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of the neuromuscular junction. It can occur as a paraneoplastic disorder associated with various types of carcinomas, usually small cell lung cancer or as an autoimmune disease. LEMS can be misdiagnosed as myasthenia gravis or as an oncological sequela, causing delays in diagnosis. We present a rare case of a male adult with confirmed LEMS occurring with pancreatic carcinoma.
Case Description UNASSIGNED
A 66-year-old man presented with a newly diagnosed pancreatic tumor. He had been experiencing weakness and fatigue in his lower extremities since the summer of 2020. Over time, the weakness progressed to include his proximal upper extremity muscles. Dysphonia, dysarthria, decreased appetite and significant weight loss were also observed. A computed tomography (CT) scan revealed a 3 cm locally resectable cystic tumor in the pancreatic head. Blood tests showed elevated carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) levels. A Whipple procedure was performed, which revealed a poorly differentiated pancreatic adenocarcinoma inside an intraductal pancreatic mucinous neoplasm. Postoperatively, the patient was admitted to the intensive care unit (ICU) because he had no spontaneous breathing and manifested areflexia signs. A train of four (TOF) monitoring of peripheral nerve stimulation was performed and pyridostigmine therapy was initiated, leading to an improvement in symptoms allowing the extubation and transfer to the peripheral ward. Further diagnostic tests revealed a LEMS and an intravenous therapy with cumulative 100 g immunoglobulin (Ig) G was initiated. Upon discharge, 10 days after starting LEMS treatment, the patient showed subjective and objective improvement in strength.
Conclusions UNASSIGNED
Paraneoplastic syndromes are more common than expected, but rare in pancreatic adenocarcinoma. They can appear before abdominal symptoms, facilitating early diagnosis. Successful treatment of cancer may eliminate paraneoplastic symptoms. LEMS may reveal pancreatic cancer. Early recognition of paraneoplastic syndromes is important for pancreatic cancer management. Further investigation is needed to evaluate the diagnostic approach for LEMS in all patients with pancreatic cancer.

Identifiants

pubmed: 37942046
doi: 10.21037/acr-22-108
pii: acr-07-22-108
pmc: PMC10628391
doi:

Types de publication

Case Reports

Langues

eng

Pagination

35

Informations de copyright

2023 AME Case Reports. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://acr.amegroups.com/article/view/10.21037/acr-22-108/coif). The authors have no conflicts of interest to declare.

Références

Neurology. 2006 Feb 14;66(3):450-1
pubmed: 16476955
Muscle Nerve. 2016 Feb;53(2):325-6
pubmed: 26452332
Asian Cardiovasc Thorac Ann. 2021 Oct 4;:2184923211051796
pubmed: 34605270
J Neurol. 2017 Sep;264(9):1854-1863
pubmed: 28608304
J Korean Med Sci. 2004 Oct;19(5):753-5
pubmed: 15483357
Muscle Nerve. 2015 Jun;51(6):936-8
pubmed: 25702627
J Neuroophthalmol. 2013 Mar;33(1):21-5
pubmed: 22926698
BMC Cancer. 2015 Nov 18;15:914
pubmed: 26582328
Muscle Nerve. 2008 Jun;37(6):786-9
pubmed: 18506722
Neurol Sci. 2021 May;42(5):2123-2127
pubmed: 33210228
Case Rep Med. 2011;2011:309149
pubmed: 21603138
J Neuroimmunol. 2008 Sep 15;201-202:153-8
pubmed: 18644631

Auteurs

Athanasios Zamparas (A)

Department of General and Visceral Surgery, St. Josef-Hospital Bochum, Ruhr University Bochum, Bochum, Germany.

Torsten Herzog (T)

Department of General and Visceral Surgery, St. Josef-Hospital Bochum, Ruhr University Bochum, Bochum, Germany.

Sarah Förster (S)

Institute of Pathology, Ruhr University Bochum, Bochum, Germany.

Ines Siglienti (I)

Department of Neurology, St. Josef-Hospital Bochum, Ruhr University Bochum, Bochum, Germany.

Waldemar Uhl (W)

Department of General and Visceral Surgery, St. Josef-Hospital Bochum, Ruhr University Bochum, Bochum, Germany.

Johanna Strotmann (J)

Department of General and Visceral Surgery, St. Josef-Hospital Bochum, Ruhr University Bochum, Bochum, Germany.

Philipp Höhn (P)

Department of General and Visceral Surgery, St. Josef-Hospital Bochum, Ruhr University Bochum, Bochum, Germany.

Classifications MeSH